HeimSGEN • BMV
add
Seagen
Við síðustu lokun
3.711,48 $
Árabil
3.711,48 $ - 3.711,48 $
Markaðsvirði
43,15 ma. USD
V/H-hlutf.
-
A/V-hlutfall
-
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | sep. 2023info | Breyting á/á |
---|---|---|
Tekjur | 648,65 m. | 27,11% |
Rekstrarkostnaður | 262,69 m. | 24,86% |
Nettótekjur | -215,79 m. | -13,09% |
Hagnaðarhlutfall | -33,27 | 11,02% |
Hagnaður á hvern hlut | -1,15 | -11,65% |
EBITDA | -209,33 m. | -19,47% |
Virkt skatthlutfall | 0,26% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | sep. 2023info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 1,24 ma. | -29,86% |
Heildareignir | 3,63 ma. | 0,42% |
Heildarskuldir | 1,08 ma. | 35,94% |
Eigið fé alls | 2,55 ma. | — |
Útistandandi hlutabréf | 188,66 m. | — |
Eiginfjárgengi | 274,52 | — |
Arðsemi eigna | -16,01% | — |
Ávöxtun eigin fjár | -21,12% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | sep. 2023info | Breyting á/á |
---|---|---|
Nettótekjur | -215,79 m. | -13,09% |
Handbært fé frá rekstri | -35,82 m. | 58,21% |
Reiðufé frá fjárfestingum | 142,49 m. | 119,31% |
Reiðufé frá fjármögnun | 15,52 m. | -15,59% |
Breyting á handbæru fé | 119,90 m. | 1.958,05% |
Frjálst peningaflæði | 71,52 m. | 1.141,10% |
Um
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Framkvæmdastjóri
Stofnsett
15. júl. 1997
Höfuðstöðvar
Vefsvæði
Starfsfólk
3.256